Effectiveness of Prophylactic Intravenous Tranexamic Acid in Preventing Postpartum Hemorrhage After Vaginal Delivery: A Quasi-Experimental Study

Objective: To evaluate the effectiveness of prophylactic TXA in reducing PPH among women undergoing vaginal delivery Methodology: This prospective non-randomized clinical trial included 192 women undergoing vaginal delivery from Sir Ganga Ram Hospital, Lahore, from March 2023 to February 2024. Inclusion criteria were age 18-40 years, gestational amenorrhea >37weeks, parity ≤3, polyhydramnios, induced labour, and previous history of PPH Women in TXA group (n=96) received intravenous TXA 100 mg/mL, and women in SOC group (n=96) received only standard of care (SOC). Gravimetric method was used to estimate blood loss. Independent sample t-test employed to compare blood loss between groups. Results: Baseline means of age (30.34 ± 8.51 vs. 30.10 ± 7.53 years, p-value 0.822), and BMI (26.01 ± 3.74 vs. 25.80 ± 3.33 Kg/m2, p-value 0.757) were comparable between the two study groups. The proportions of age categories (p-value 0.826), BMI classes (p-value 0.626) and parity (p-value 0.688) were also similar in both groups PPH immediately after delivery of placenta (323.59 ± 49.91 vs. 424.88 ± 41.28 ml; p-value